Andreea Iordache

Junior Manager Science & Regulatory Affairs @VaccinesEurope @EFPIA | Soft-Skills Trainer & Alumna @EPSA_Online | 🇷🇴 Pharmacist | All views are personal

[Sini Eskola @sinieskola]

Come to play with us @DIA_Europe Exhibition Area - How can we close the gap to make Europe a world leader of medical science and make our regulatory framework future proof for unprecedented innovation to help #patients for decades to come? @EFPIA

[Andreea Iordache @AndreeaI24]

💉Vaccination is recognised to be a cost-effective tool in the fight against #AMR.

🔛Explore our recommendations for an end-to-end approach to ensure the development, availability and use of vaccines to address AMR, in synergy with other available tools.

[VaccinesEurope @VaccinesEurope]

By 2050, #AMR could be associated with up to 10 million deaths and more than $1 trillion in annual healthcare costs. To fight AMR, we must use every tool available – starting with vaccination. https://t.co/vLck3zDt1g #WeWontRest

[Nathalie Moll @NathalieMoll]

Valuable, concentrated, impactful input at #PoliticoHealthcare this morning. Looking fwd to this panel now on #PharmaStrategy with @AstraZeneca , @EU_Health & the @Europarl_EN @CristianSBusoi @nicogoncas
@EFPIA

[Andreea Iordache @AndreeaI24]

💡Mateusz Hasso-Agopsowicz @WHO emphasising the value vaccines have in the fight against AMR.

Despite their potential and demonstrated value, vaccines remain underrecognised tools to prevent AMR.

#WVCEU @VaccinesEurope

[Andreea Iordache @AndreeaI24]

#WVEU is back 🤩 Starting with an exciting keynote on getting ahead of the curve on pandemic prearedness.

🔸️How to extrapolate the lessons from COVID to other pathogens?

🔸️How to mitigate the remaining vulnerabilities to be better prepared?

@vaccinenation @VaccinesEurope

[Andreea Iordache @AndreeaI24]

🗣Great discussion at the #EUFluDay on the importance of improving the uptake of seasonal influenza vaccines.

👩‍⚕️👨‍⚕️Healthcare professionals are a trusted source of information and have a central role in the immunisation of citizens.

@VaccinesEurope

[VaccinesEurope @VaccinesEurope]

Isabel De la Mata @EU_Health has a clear message - to tackle influenza we need support for enhanced surveillance and vaccination at all levels! #EUFluDay

[VaccinesEurope @VaccinesEurope]

Kicking off #EUFluDay with words from MEP @istvan_ujhelyi

He emphasises the need to make noise here in Brussels! Today we are here for health professionals to discuss how we can support them.

[VaccinesEurope @VaccinesEurope]

While the #COVID19 pandemic demonstrated the vital importance of the vaccines industry, the number of vaccine clinical trials taking place in the EU is declining.

Discover how we can reverse it: https://t.co/RxSVJL7A2m #WeWontRest

[Andreea Iordache @AndreeaI24]

@EFPIA Rentrée is back! 🤩 Starting with an exciting discussion moderated by @NathalieMoll proving that it is extremely important where innovation happens. Speakers representing both SMEs and large companies highlight the value brought by innovation to patients.

#WeWontRest

[VaccinesEurope @VaccinesEurope]

New data shows the urgent need to reinvigorate the EU's position as a leader in vaccine innovation & ensure the continued health & prosperity of all Europeans.

How? Read our policy asks: https://t.co/RxSVJL7A2m #WeWontRest

[VaccinesEurope @VaccinesEurope]

Our new joint position paper highlights the vital role of vaccines in addressing unmet medical need (UMN).

The takeaway? We must prioritize a UMN concept that can be part of a paradigm shift in health encompassing care to prevention. https://t.co/ebbsS1IQWu #EUPharmaLegislation

[VaccinesEurope @VaccinesEurope]

We are launching our Manifesto today, calling on the EU to put in place an #EUImmunisationStrategy. Europeans' health, prosperity and the ability to harness innovation to realise the full potential of vaccination must remain high on the political agenda
https://t.co/0ny3aPKSA4

[VaccinesEurope @VaccinesEurope]

Vaccine shortages in the EU is an issue that can’t be solved in silo. Continuous cooperation between all stakeholders and policies for flexibility of vaccines supply are critical to address this issue https://t.co/zOGrB4SqIj #WeWontResVaccine shortages in the EU is an issue that can’t be solved in silo. Continuous cooperation between all stakeholders and policies for flexibility of vaccines supply are critical to address this issue https://t.co/zOGrB4SqIj #WeWontResVaccine shortages in the EU is an issue that can’t be solved in silo. Continuous cooperation between all stakeholders and policies for flexibility of vaccines supply are critical to address this issue https://t.co/zOGrB4SqIj #WeWontResVaccine shortages in the EU is an issue that can’t be solved in silo. Continuous cooperation between all stakeholders and policies for flexibility of vaccines supply are critical to address this issue https://t.co/zOGrB4SqIj #WeWontResVaccine shortages in the EU is an issue that can’t be solved in silo. Continuous cooperation between all stakeholders and policies for flexibility of vaccines supply are critical to address this issue https://t.co/zOGrB4SqIj #WeWontResVaccine shortages in the EU is an issue that can’t be solved in silo. Continuous cooperation between all stakeholders and policies for flexibility of vaccines supply are critical to address this issue https://t.co/zOGrB4SqIj #WeWontRest

[VaccinesEurope @VaccinesEurope]

It usually takes years to produce a vaccine. The manufacturing process is complex and it involves multiple steps. This is why early understanding of demand is crucial to ensure appropriate #VaccinesSupply https://t.co/Bjg7mjN7KH #WeWontRest

[VaccinesEurope @VaccinesEurope]

Vaccines are complex biological products with lengthy manufacturing and control processes. In our new paper, we look into how long it takes to produce different types of vaccines, and what might delay, as well as improve the production process https://t.co/Bjg7mjN7KH #WeWontResVaccines are complex biological products with lengthy manufacturing and control processes. In our new paper, we look into how long it takes to produce different types of vaccines, and what might delay, as well as improve the production process https://t.co/Bjg7mjN7KH #WeWontResVaccines are complex biological products with lengthy manufacturing and control processes. In our new paper, we look into how long it takes to produce different types of vaccines, and what might delay, as well as improve the production process https://t.co/Bjg7mjN7KH #WeWontResVaccines are complex biological products with lengthy manufacturing and control processes. In our new paper, we look into how long it takes to produce different types of vaccines, and what might delay, as well as improve the production process https://t.co/Bjg7mjN7KH #WeWontResVaccines are complex biological products with lengthy manufacturing and control processes. In our new paper, we look into how long it takes to produce different types of vaccines, and what might delay, as well as improve the production process https://t.co/Bjg7mjN7KH #WeWontRest

[Andreea Iordache @AndreeaI24]

A real inspiration for all of us 😍

[Financial Times @FT]

Moldova’s Maia Sandu: ‘They would like to remake the Soviet Union’ https://t.co/tm5BKrQFgU

[Andreea Iordache @AndreeaI24]

🤩 Excited to present to pharmaceutical students across Europe about the current trends in the vaccine field and the importance of vaccination. @VaccinesEurope

[Catharina Knol @Catharina_EPSA]

@EPSA_Online WEBINAR🇪🇺👩‍🎓I @AndreeaI24 from @VaccinesEurope gives pharmacy students from all over the EU inspiring insights into the current innovative development of vaccines #VaccinesWork.

[VaccinesEurope @VaccinesEurope]

There are 100 vaccine candidates in development by our member companies using 10 different technology platforms, shares @AndreeaI24 at @EPSA_Online webinar #VaccinesInnovation

[VaccinesEurope @VaccinesEurope]

📢 Our first newsletter for 2023 is out ✉️ See what we've been up to in the first few months of the year and subscribe here ➡️ https://t.co/QYWpuLRElE